Redx will become a key upcoming player in IPF treatment with FDA’s ODD for zelasudil: GlobalData Read more
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic pulmonary fibrosis Read more